Abivax SA - ADR

The momentum for this stock is not very good. Abivax SA - ADR is not a good value stock. Abivax SA - ADR is not a good growth stock. Abivax SA - ADR is not very popular among insiders. Tradey thinks it is not wise to invest in Abivax SA - ADR.

News

Abivax management to meet virtually with Piper Sandler

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Abivax presents first-half 2024 financial results

Globe Newswire Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to Q4 2025 PARIS, France, September 9, 2024, 10:00 p.m. CEST Abivax SA (Euronext...\n more…

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

Globe Newswire Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the...\n more…

Buy Rating Affirmed on Abivax SA as Phase 3 Trial of Obefazimod Shows Promise

TipRanks Financial Blog Julian Harrison, an analyst from BTIG, maintained the Buy rating on Abivax SA Sponsored ADR (ABVX - Research Report). The associated price target r...\n more…

Abivax Progresses on Ulcerative Colitis Phase 3 Trial

TipRanks Financial Blog Abivax SA (FR:ABVX) has released an update. Abivax SA, a biotech company, is on track with its Phase 3 ABTECT trial for obefazimod in treating ulcerative colitis, w...\n more…

Abivax Announces Share Capital and Voting Rights

TipRanks Financial Blog Abivax SA (FR:ABVX) has released an update. Abivax, a clinical-stage biotech company, has disclosed its share capital and voting rights as of May 31, 2024, revealin...\n more…